U.S. AtuRNAi Patent Allowance Builds on European Equivalent Granted in
2007, Expanding Commercial Protection
LONDON, July 31 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN), a leading European RNAi focused biotechnology company, today announced that the United States Patent and Trademark Office has allowed the Company's core RNAi patent application. The Patent Office issued a 'Notice of Allowance' for patent application 10/633,630, "Interfering RNA Molecules," which covers stabilized, small interfering RNA (siRNA) molecules with defined positional modifications. The claims cover siRNA molecules that are "blunt ended," as well as molecules with one or more "overhangs" and specifically cover Silence Therapeutics' proprietary siRNA molecules, known as "AtuRNAi".
The company also announced today it has received a Notice of Acceptance from the Australian Patent Office for patent application No. 2003260370 entitled "Further novel forms of interfering RNA molecules." The European equivalent of the US and Australian patent applications was granted by the European Patent Office in January 2007.
Iain Ross, Chairman & CEO of Silence Therapeutics, said, "This is a major milestone for Silence, our partners and investors. This patent allowance protects our AtuRNAi technology and our proprietary siRNA molecules in the United States, the largest pharmaceutical market in the world. Silence already has a strong, proprietary position in the RNAi space and this allowance builds further on our global patent portfolio. With the U.S. patent allowance, we are now significantly better positioned to achieve our goal of becoming one of the leading companies in the field of RNAi therapeutics and delivery."
Silence considers its AtuRNAi to be best-in-class siRNA molecules based
on important advantages over conventional siRNA molecules, including
increased stability against nuclease degradation and an increased serum
half-life, while ret
|SOURCE Silence Therapeutics plc|
Copyright©2008 PR Newswire.
All rights reserved